-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8

Benzinga·11/05/2026 19:56:44
Listen to the news
Leerink Partners analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and raises the price target from $5 to $8.